Neuro, All I'm saying is don't extrapolate too far based on a couple iffy data points. They found a CMO, that's good, but it doesn't necessarily equate to a clean bill of health for Cortex's future as a company. Tran came from 'XenoPort', not exactly a big name pharma. If he's so great, why did he leave Lilly? For all we know, Tran might have been the only applicant for the job who didn't back out when the IND was rejected.
Well, 15th post of the day, later.
Market Data 
Markets 
AI
